Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Top Research Reports For Alphabet, Novo Nordisk & Enterprise Products

Published 10/10/2016, 01:57 AM
Updated 07/09/2023, 06:31 AM

Monday, October 10, 2016

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (NASDAQ:GOOGL), Novo Nordisk (CO:NOVOb) (NVO) and Enterprise Products Partners (EPD).

Google parent Alphabet shares lagged the broader market and the Tech sector this year, but the company remains well positioned for outperformance in the long run given its focus on innovation, strategic acquisitions, the Android OS and a number of other diversification moves. In its Oct 4 event, the tech giant unveiled a range of new products including two smartphones, a 5.0 inch Pixel and a 5.5 inch Pixel XL, and an Android virtual reality headset, Daydream. However, growing competition and legal hassles remained as major headwinds. (You can read the full research report on Alphabet here>>)

Novo Nordisk shares have been laggards this year, as the Danish pharmaceutical giant has been grappling with a number of a company-specific issues on top of the unfavorable political/regulatory backdrop for the space as a whole. The company's strong presence in the Diabetes Care market and focus on therapeutic proteins within insulin is a big positive. To that end, Victoza remains a key growth area for the company. But a slew of patent expirations, growing pricing pressures for a number of its drugs and the recent decision to discontinue the development of liraglutide as a joint therapy to insulin in type I diabetes remain headwinds. The Zacks analyst discusses the pros & cons of investing in Novo Nordisk shares at this stage. (You can read the full research report on Novo Nordisk here>>)

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Enterprise Products Partners shares have performed in line with the broader market this year, but lagged the energy space as a whole on NGL pricing issues and the recent uptrend in long-term interest rates. These issues notwithstanding, the Zacks analyst likes the partnership's large scale and diverse midstream asset base and multi-billion dollar projects under construction, which are likely to support meaningful distribution growth. (You can read the full research report on Enterprise Products Partners here>>)

Other noteworthy reports we are featuring today include Twitter (TWTR), Textron (NYSE:TXT) and Xerox (NYSE:XRX).

Free Access: All Zacks Research Reports

Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>

You can find all of today's stock research reports here>>

Sheraz Mian

Director of Research

Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

Bank of the Ozarks (OZRK) Hikes Dividend, Costs a Concern

The Zacks Analyst thinks that persistent hike in dividend by Bank of the Ozarks will boost investors' confidence in the stock. However, mounting non-interest expenses remain a matter of concern.

Twitter's (TWTR) Buyout Rumors Losing Steam on Scarce Bids

The covering analyst observes that Twitter's vast data is appealing for buyers, but the plethora of issues like sluggish user growth complicated by hefty price tag are proving big impediments.

Cousins (CUZ) Closes Merger with Parkway Properties

According to the Zacks analyst, the merger with Parkway Properties and Houston asset spin-off will help Cousins bolster its presence in key regions and exit troubled market.

Xerox (XRX) Remains Poised for Healthy Long-Term Growth

Xerox's three-year strategic transformation program aims incremental savings of $600 million across all segments and intends to realize cumulative cost reduction of $2.4 billion to spur growth.

Textron's (TXT) Growth Strategy Impresses

The Zacks Analyst believes that Textron's systematic inorganic growth strategy, new product offerings will drive profitability.

Exposure to Low Interest Rates a Drag on W.R. Berkley (WRB)

The covering analyst believes that W.R. Berkley's exposure to an intensely competitive insurance market with low interest rate scenario is a concern.

LabCorp (LH) Poised On Sequenom Acquisition, Forex Woes Hurt

Despite the strengthening dollar, the Zacks analyst believes Labcorp is gaining prominence in the market with the recent acquisition of Sequenom.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
New Upgrades

SVB Financial (SIVB) Remains Well Positioned for Growth

According to the Zacks Analyst, SVB Financial is poised to capitalize on future opportunities based on its sturdy capital position. Also, rising non-interest income will aid top-line growth.

Analog Devices (ADI) Rides High on Strong Market Position

The covering analyst believes that Analog Devices is well positioned in markets such as industrial, auto and communication, which have impressive growth prospects.

Big 5's (BGFV) Strategic Efforts to Keep it on Growth Path

The Zacks analyst thinks that Big 5's merchandising plans, eCommerce growth and solid store network will help it capture market share and fuel growth. It's third quarter view also remain upbeat.

New Downgrades

Stericycle (NASDAQ:SRCL) Plagued by Macroeconomic Challenges, Margin Woes

Stericycle has lowered its earnings guidance for 2016 due to macroeconomic challenges and unfavorable foreign exchange rates as margin woes related to high operating costs linger.

Low Interest Rate, Stiff Competition Dragging Intercontinental (ICE)

The Zacks analyst believes stiff competition, low interest rate, challenging regulations and volatile industry trends raise concern over Intercontinental Exchange's operational results.

Competitive Market and Slower Omnigraft Ramp Hurt Integra (IART)

According to the covering analyst, a highly competitive market for hospital/physician office instrumentation and slower ramp of Omnigraft are going to affect Integra Lifesciences' performance.



XEROX CORP (XRX): Free Stock Analysis Report

TEXTRON INC (TXT): Free Stock Analysis Report

TWITTER INC (TWTR): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


ALPHABET INC-A (GOOGL): Free Stock Analysis Report

ENTERPRISE PROD (EPD): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.